https://www.businesswire.com/news/home/20240305290262/en/Verastem-Oncology-Announces-Preclinical-Presentations-for-New-Oral-G12D-Inhibitor-and-for-Avutometinib-and-Defactinib-Combination-as-a-Backbone-of-Therapy-for-RASMAPK-Driven-Cancers-at-AACR-Annual-Meeting-2024
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that preclinical data will b...
verastem oncologyannouncespreclinicalpresentationsnew
https://aijourn.com/verastem-oncology-granted-fast-track-designation-for-combination-of-avutometinib-and-sotorasib-for-the-treatment-of-kras-g12c-mutant-non-small-cell-lung-cancer-nsclc/
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for...
Jan 18, 2024 - BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today
fast track designationverastem oncologygrantedcombinationavutometinib